Latest & greatest articles for parkinson's disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on parkinson's disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on parkinson's disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for parkinson's disease

1. Dual-task training on gait, motor symptoms, and balance in patients with Parkinson's disease: a systematic review and meta-analysis

Dual-task training on gait, motor symptoms, and balance in patients with Parkinson's disease: a systematic review and meta-analysis Dual-task training on gait, motor symptoms, and balance in patients with Parkinson's disease: a systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 (...) in patients with Parkinson's disease: a systematic review and meta-analysis , , , , , Affiliations Expand Affiliations 1 School of Sport Science, Shanghai University of Sport, Shanghai, China. 2 Department of Rehabilitation Sciences, Ningbo College of Health Sciences, Zhejiang, Ningbo, China. 3 School of Martial Arts, Shanghai University of Sport, Shanghai, China. PMID: 32660265 DOI: Item in Clipboard Dual-task training on gait, motor symptoms, and balance in patients with Parkinson's disease

2020 EvidenceUpdates

2. Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson`s disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study

Actions Dyskinesias / therapy Actions Female Actions Humans Actions Longitudinal Studies Actions Male Actions Middle Aged Actions Parkinson Disease / therapy* Actions Severity of Illness Index Actions Subthalamic Nucleus / metabolism* Actions Treatment Outcome Actions Associated data ClinicalTrials.gov/NCT01839396 Actions Grant support LinkOut - more resources Full Text Sources Medical Full-text links [x] [x] Citation text Copy Download .nbib Format: Send To [x] Connect National Center (...) Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson`s disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage

2020 EvidenceUpdates

3. Effects of a core stabilization training program on balance ability in persons with Parkinson`s disease: a randomized controlled trial

Effects of a core stabilization training program on balance ability in persons with Parkinson`s disease: a randomized controlled trial Effects of a Core Stabilization Training Program on Balance Ability in Persons With Parkinson's Disease: A Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National (...) RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Clin Rehabil Actions . 2020 Jun;34(6):764-772. doi: 10.1177/0269215520918631. Epub 2020 Apr 29. Effects of a Core Stabilization Training Program on Balance Ability in Persons With Parkinson's Disease: A Randomized Controlled Trial , , , , , Affiliations Expand Affiliation 1 Department of Physical Therapy, Faculty of Health Sciences, University of Granada, Granada

2020 EvidenceUpdates

4. Opicapone (Ongentys) - To treat patients with Parkinson’s disease experiencing “off” episodes

Opicapone (Ongentys) - To treat patients with Parkinson’s disease experiencing “off” episodes Drug Approval Package: ONGENTYS U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ONGENTYS Company: Neurocrine Biosciences, Inc. Application Number: 212489 Approval Date: 04/24/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review

2020 FDA - Drug Approval Package

5. Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease. (Abstract)

Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease. We report the implantation of patient-derived midbrain dopaminergic progenitor cells, differentiated in vitro from autologous induced pluripotent stem cells (iPSCs), in a patient with idiopathic Parkinson's disease. The patient-specific progenitor cells were produced under Good Manufacturing Practice conditions and characterized as having the phenotypic properties of substantia nigra pars compacta neurons; testing (...) in a humanized mouse model (involving peripheral-blood mononuclear cells) indicated an absence of immunogenicity to these cells. The cells were implanted into the putamen (left hemisphere followed by right hemisphere, 6 months apart) of a patient with Parkinson's disease, without the need for immunosuppression. Positron-emission tomography with the use of fluorine-18-L-dihydroxyphenylalanine suggested graft survival. Clinical measures of symptoms of Parkinson's disease after surgery stabilized or improved

2020 NEJM

6. Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. (Abstract)

Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. Studies suggest that dihydropyridine calcium-channel blockers may be associated with reduced risk for Parkinson disease (PD).To assess the effect of isradipine, a dihydropyridine calcium-channel blocker, on the rate of clinical progression of PD.Multicenter, randomized, parallel-group, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT02168842).57 Parkinson Study Group sites in North America.Patients (...) with early-stage PD (duration <3 years) who were not taking dopaminergic medications at enrollment.5 mg of immediate-release isradipine twice daily or placebo for 36 months.The primary outcome was change in the Unified Parkinson's Disease Rating Scale (UPDRS) parts I to III score measured in the antiparkinson medication "ON" state between baseline and 36 months. Secondary outcomes included time to initiation and use of antiparkinson medications, time to onset of motor complications, change in nonmotor

2020 Annals of Internal Medicine

7. Diagnosis and Treatment of Parkinson Disease: A Review. (Abstract)

Diagnosis and Treatment of Parkinson Disease: A Review. Parkinson disease is the most common form of parkinsonism, a group of neurological disorders with Parkinson disease-like movement problems such as rigidity, slowness, and tremor. More than 6 million individuals worldwide have Parkinson disease.Diagnosis of Parkinson disease is based on history and examination. History can include prodromal features (eg, rapid eye movement sleep behavior disorder, hyposmia, constipation), characteristic (...) movement difficulty (eg, tremor, stiffness, slowness), and psychological or cognitive problems (eg, cognitive decline, depression, anxiety). Examination typically demonstrates bradykinesia with tremor, rigidity, or both. Dopamine transporter single-photon emission computed tomography can improve the accuracy of diagnosis when the presence of parkinsonism is uncertain. Parkinson disease has multiple disease variants with different prognoses. Individuals with a diffuse malignant subtype (9%-16

2020 JAMA

8. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study

: Affiliations 1 Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Clintrex, Sarasota, FL, USA. Electronic address: warren.olanow@clintrex.com. 2 Department of Neurology, Emory University, Atlanta, GA, USA. 3 Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, OH, USA. 4 Department of Neurology, University of South Florida, Tampa, FL, USA. 5 Barrow Neurological Institute, Phoenix, AZ, USA. 6 Parkinson's Disease and Movement Disorders (...) and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA. 7 University of Kansas Medical Center, University of Kansas, Kansas City, KS, USA. 8 Clintrex, Sarasota, FL, USA. 9 Sunovion, Marlborough, MA, USA. PMID: 31818699 DOI: Item in Clipboard Full-text links Cite Abstract Background: Many patients with Parkinson's disease have potentially disabling off episodes that are not predictably responsive to levodopa. In this study, we assessed the safety and efficacy of apomorphine sublingual film

2020 EvidenceUpdates

9. Parkinson's disease: When should I suspect Parkinson's disease?

, but rarely involves the head, neck, or voice. Is absent in up to 30% of people at disease onset. Balance problems and/or gait disorders. Postural instability is suggested by the 'pull test' — a tendency to fall backwards after a sharp pull from the examiner. This may be suggestive of Parkinson's disease if unrelated to primary visual, cerebellar, vestibular, or proprioceptive dysfunction. These clinical features are usually unilateral in early disease, but are progressive and may become bilateral (...) Guidelines Network (SIGN) clinical guideline Diagnosis and pharmacological management of Parkinson's disease [ ], and an evidence-based review article European Federation of Neurological Societies (EFNS)/ Movement Disorder Society-European Section (MDS-ES) recommendations for the diagnosis of Parkinson's disease [ ], a case-control study on pre-diagnostic presentations of Parkinson's disease [ ], and expert opinion in a review article on Parkinson's disease [ ]. The NICE clinical guideline recommends

2020 NICE Clinical Knowledge Summaries

10. Assessment of an Objective Method of Dyskinesia Measurement in Parkinson's Disease. Full Text available with Trip Pro

Assessment of an Objective Method of Dyskinesia Measurement in Parkinson's Disease. The goal of this study was to validate an objective method of measuring levodopa induced dyskinesia in Parkinson's disease (PD).To characterize agreement between the clinician-based measure and a force plate, we assessed dyskinesia in PD subjects participating in a randomized and blinded clinical trial of an adenosine A2A anatagonist. Convergent validity and intra-class correlations were evaluated between

2019 Movement disorders clinical practice Controlled trial quality: uncertain

11. Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease. Full Text available with Trip Pro

Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease. Neurogenic orthostatic hypotension (nOH) is associated with neurodegenerative conditions, may cause symptoms of end-organ hypoperfusion, increases fall risk, and can negatively impact quality of life. Droxidopa is approved for the treatment of symptomatic nOH in adults. As the largest subpopulation of patients with nOH has a diagnosis of Parkinson disease (PD

2019 Movement disorders clinical practice Controlled trial quality: uncertain

12. Istradefylline (Nourianz) - Parkinson's disease

and Uncertainties Conclusions and Reasons Analysis of Condition ? The condition treated was advanced Parkinson's disease which is operationally defined as patients taking levodopa and experiencing OFF episodes. Istradefylline was given to these patients as adjunctive treatment. The pivotal trials were adequate for investigating effects on istradefylline on adult patients with advanced Parkinson's disease. Current Treatment Options ? There are many approved treatments as adjunctive therapy for patients (...) Istradefylline (Nourianz) - Parkinson's disease CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022075Orig1s000 CLINICAL REVIEW(S) (b) (4) Clinical Review Natalie Branagan, MD NDA 022075 Nourianz/istradefylline CLINICAL REVIEW Application Type NDA Application Number(s) 022075 Priority or Standard Class 2 Resubmission Submit Date(s) February 27, 2019 Received Date(s) February 27, 2019 PDUFA Goal Date August 27, 2019 Division/Office DNP Reviewer Name(s) Natalie Branagan, MD Review

2019 FDA - Drug Approval Package

13. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial Full Text available with Trip Pro

of group assignments. Both interventions were home based, requiring 30-45 min training three times per week for 6 months. Both groups received a motivational app and remote supervision. Home trainers were enhanced with virtual reality software and real-life videos providing a so-called exergaming experience (ie, exercise enhanced by gamified elements). The primary outcome was the between-group difference in the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor (...) Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial High-intensity aerobic exercise might attenuate the symptoms of Parkinson's disease, but high-quality evidence is scarce. Moreover, long-term adherence remains challenging. We aimed to evaluate the effectiveness of aerobic exercise-gamified and delivered at home, to promote adherence-on relieving motor symptoms in patients with Parkinson's disease with mild

2019 EvidenceUpdates

14. Levodopa (Inbrija) - Parkinson’s disease

with Parkinson’s disease, the cells in the brain that produce dopamine, a neurotransmitter important for controlling movement, begin to die and the amount of dopamine in the brain decreases. Inbrija contains levodopa which converts into dopamine in the brain and helps to restore dopamine levels, thereby improving the symptoms of the condition. Because Inbrija is inhaled, it can supply extra levodopa (and hence dopamine) quickly when needed during an ‘off’ period. What benefits of Inbrija have been shown (...) malignant syndrome or rhabdomyolysis. For the full list of side effects and restrictions, see the package leaflet. Why is Inbrija authorised in the EU? Studies show that Inbrija is effective at reducing symptoms during ‘off’ periods in patients with Parkinson’s disease on levodopa/dopa-decarboxylase-inhibitor treatment. The safety of the medicine is in line with other similar medicines. Because it is inhaled, Inbrija provides rapid relief of symptoms, which improves patients’ quality of life

2019 European Medicines Agency - EPARs

15. Canadian guideline for Parkinson disease

and written form. n Discussions should aim to achieve a balance between providing realistic information and promoting optimism. n Families and caregivers should be informed about the condition and available support services. DIAGNOSIS AND PROGRESSION n Parkinson disease should be suspected in anyone with tremor, stiness, slowness, balance problems or gait disorders. n CT or MRI brain scanning should not be routinely used to diagnose Parkinson disease. n Patients, especially young, who request genetic (...) to achieve a balance between providing realistic information and promoting optimism. n Families and caregivers should be informed about the condition and available support services. DIAGNOSIS AND PROGRESSION n Parkinson disease should be suspected in anyone with tremor, stiness, slowness, balance problems or gait disorders. n CT or MRI brain scanning should not be routinely used to diagnose Parkinson disease. n Patients, especially young, who request genetic testing should be assessed by a movement

2019 CPG Infobase

16. Safinamide (Xadago) for the treatment of adult patients with idiopathic Parkinson's disease

Safinamide (Xadago) for the treatment of adult patients with idiopathic Parkinson's disease Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson's disease | Report | National Health Care Institute You are here: Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson's disease Search within English part of National Health Care Institute Search Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson's disease

2019 National Health Care Institute (Zorginstituut Nederland)

17. Safinamide (Onstryv) - idiopathic Parkinson's disease

Safinamide (Onstryv) - idiopathic Parkinson's disease Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1

2019 Health Canada - Drug and Health Product Register

18. Land Plus Aquatic Therapy Versus Land-Based Rehabilitation Alone for the Treatment of Freezing of Gait in Parkinson Disease: A Randomized Controlled Trial Full Text available with Trip Pro

effect of land-based therapies plus aquatic therapy in patients with PD who have FOG.The objective was to investigate the effectiveness of a multidisciplinary, intensive, motor-cognitive rehabilitation treatment (MIRT) in improving FOG and whether implementation with aquatic therapy (MIRT-AT) adds further benefits.The design consisted of a single-blind, parallel-group, 1:1 allocation ratio, randomized trial.The Department of Parkinson Disease, Movement Disorders and Brain Injury Rehabilitation (...) Land Plus Aquatic Therapy Versus Land-Based Rehabilitation Alone for the Treatment of Freezing of Gait in Parkinson Disease: A Randomized Controlled Trial Freezing of gait (FOG) is one of the most disabling symptoms of Parkinson disease (PD). Different land-based rehabilitation approaches based on motor and cognitive strategies can be effective in treating FOG. Although there are data about the efficacy of aquatic therapy in ameliorating this phenomenon, no study has explored the combined

2019 EvidenceUpdates

19. Randomized trial of care management to improve Parkinson disease care quality (Abstract)

Randomized trial of care management to improve Parkinson disease care quality To test effects on care quality of Chronic Care Model-based Parkinson disease (PD) management.This 2-group stratified randomized trial involved 328 veterans with PD in southwestern United States. Guided care management, led by PD nurses, was compared to usual care. Primary outcomes were adherence to 18 PD care quality indicators. Secondary outcomes were patient-centered outcome measures. Data sources were telephone (...) of the changes over time was in the positive Patient Health Questionnaire-2 depression screen for intervention minus usual care (-11.52 [95% CI -20.42, -2.62]).A nurse-led chronic care management intervention, Care Coordination for Health Promotion and Activities in Parkinson's Disease (CHAPS), substantially increased adherence to PD quality of care indicators among veterans with PD, as documented in the EMR. Of 8 secondary outcomes assessed, a screening measure for depressive symptomatology was the only

2019 EvidenceUpdates

20. Comparative Effectiveness of mHealth-Supported Exercise Compared With Exercise Alone for People With Parkinson Disease: Randomized Controlled Pilot Study Full Text available with Trip Pro

Comparative Effectiveness of mHealth-Supported Exercise Compared With Exercise Alone for People With Parkinson Disease: Randomized Controlled Pilot Study Declining physical activity commonly occurs in people with Parkinson disease (PD) and contributes to reduced functional capacity and quality of life.The purpose of this study was to explore the preliminary effectiveness, safety, and acceptability of a mobile health (mHealth)-mediated exercise program designed to promote sustained physical (...) . Daily steps and moderate-intensity minutes were measured using a step activity monitor for 1 week at baseline and again at 12 months. Secondary outcomes included the 6-Minute Walk Test, Parkinson Disease Questionnaire 39 mobility domain, safety, acceptability, and adherence.Both groups increased daily steps, moderate-intensity minutes, and 6-Minute Walk Test, with no statistically significant between-group differences observed. In the less active subgroup, changes in daily steps and moderate

2019 EvidenceUpdates